Teva Pharmaceutical is recommended as a buy with a target price of $58.60. It is a leading global generic and brand name pharmaceutical company with attractive growth prospects through expanding markets and recent acquisitions. The company provides stable cash flows from its diversified portfolio of generic and innovative drugs, complementing an overweight healthcare strategy.